{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-013370","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2023-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.440289+00:00","generated_at":"2026-06-16T23:47:22.767491+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Erasca reports Phase 1b data for ERAS-601+cetuximab; MTD 40mg BID; tolerable safety","bullets":["Promising initial safety from Phase 1b FLAGSHP-1 dose escalation for ERAS-601 + cetuximab in advanced solid tumors.","Only Grade 1-2 TRAEs at or below the combination MTD; ERAS-601 MTD 40 mg BID 3/1 with cetuximab 500 mg/m2 Q2W.","Data presented at AACR 2023; expects initial Phase 1b dose expansion data in HPV-negative HNSCC in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-013370","json":"https://secwatch.observer/filing/0000950170-23-013370.json","markdown":"https://secwatch.observer/filing/0000950170-23-013370.md","text":"https://secwatch.observer/filing/0000950170-23-013370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023013370/0000950170-23-013370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023013370/eras-20230418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T23:47:22.767491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}